lindane (Rx)

Brand and Other Names:
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

lotion/shampoo

  • 1%

Scabies

Lotion: Apply thin layer and massage on skin on entire body except face; bathe and remove drug 8-12 hr after application

Head Lice or Crab Lice

Apply 1-2 oz of shampoo (not to exceed 2 oz) on dry hair; leave on 4 min, lather, rinse, remove nits with fine comb

One time application usually sufficient; may use other pediculicide in 1 wk if necessary

Dosage Forms & Strengths

lotion/shampoo

  • 1%

Scabies

Lotion: Apply thin layer and massage on skin on entire body except face; bathe and remove drug 8-12 hr after application

Head Lice or Crab Lice

Apply 1-2 oz of shampoo (not to exceed 2 oz) on dry hair; leave on 4 min, lather, rinse, remove nits with fine comb

One time application usually sufficient; may use other pediculicide in 1 wk if necessary

Next:

Adverse Effects

Frequency Not Defined

Slight local irritation (including eczematous eruptions, rash, conjunctivitis)

Repeated application frequently causes contact dermatitis

CNS toxicity (seizures)

Cardiac arrhythmia

Ataxia

Dizziness

Restlessness

Pain

Seizure

Alopecia

Urticaria

Hematuria

Pulmonary edema

Hepatitis

Nausea/vomiting

Paresthesia

Aplastic anemia

Previous
Next:

Warnings

Black Box Warnings

Neurotoxicity, including seizures and death, has been reported with repeat or prolonged application, and rarely with single application.

Use with caution in those at risk for neurotoxicity including infants, children, elderly persons, those who weigh <50 kg, or those with a history of seizures. It is contraindicated in premature infants and in those with uncontrolled seizure disorders. Counseling the patient on proper use is required.

Use only in patients who have failed first line treatments

Provide patient with medication use guide with instructions on how to use

Contraindications

Premature neonates (<28 do) (increased absorption), uncontrolled seizure disorder, hypersensitivity, Norwegian (crusted) scabies, skin conditions that may increase systemic absorption (weeping surface, inflamed skin etc)

Cautions

Not first-line

Risk of serious neurotoxicity in children weighing <50 kg

Use caution in hepatic impairment

HIV infection, history of head trauma or a prior seizure, CNS tumor, severe hepatic cirrhosis, excessive use of alcohol, abrupt withdrawal from alcohol or sedatives, concomitant use of medications known to lower seizure threshold

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: distributed in breast milk, do not nurse for 24 hr post-application (express milk & discard)

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Following absorption through the chitinous exoskeleton of arthropods, cyclic chlorinated hydrocarbons like lindane presumably stimulate the nervous system, resulting in seizures & death of parasite

Pharmacokinetics

Absorption: <13% (slowly & incompletely absorbed through intact skin when applied topically)

Metabolism: Liver

Excretion: Urine & feces

Peak serum time: 6 hr

Excretion: Urine; feces

Half-life: 17-22 hr (children)

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.